Healthcare / Drug Manufacturers - GeneralShanghai
$17.42
-0.40 (-2.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-29.4M · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
134.0x
↑EV/EBITDA
53.6x
↑ROE
25.2%
↑Gross Margin
47.8%
↓Debt/Equity
2.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.8%
FCF CAGR
—
FCF margin
-9.2%
FCF / Net income
-1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $211.8M · net income $17.6M · FCF $-19.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $211.8M | $211.8M | $217.3M | $121.8M | $108.9M |
| Net Income | $17.6M | $17.6M | $15.2M | $-38.3M | $-67.5M |
| EBITDA | $42.1M | $42.1M | $53.2M | $-14.1M | $-46.6M |
| EPS | 0.14 | 0.14 | 0.13 | -0.31 | -0.55 |
| Gross Margin | 47.8% | 47.8% | 47.4% | 21.8% | 22.9% |
| Operating Margin | 8.1% | 8.1% | 15.7% | -18.0% | -26.1% |
| Net Margin | 8.3% | 8.3% | 7.0% | -31.4% | -62.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.37 | 2.37 | 2.88 | 3.09 | -7.95 |
| Current Ratio | 0.84 | 0.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.4M | $-19.4M | $-57.2M | $-29.4M | $-22.9M |
| Returns | |||||
| ROE | 25.2% | 25.2% | 29.1% | -103.1% | 462.9% |
| Valuation | |||||
| P/E | 134.00 | 134.00 | 65.65 | — | — |
| EV/EBITDA | 53.64 | 53.64 | 20.41 | — | — |
| P/B | 30.30 | 30.30 | 19.11 | 36.37 | — |
| Growth & Yield | |||||
| Revenue Growth | -2.6% | -2.6% | 78.4% | 11.8% | — |
| EPS Growth | 15.6% | 15.6% | 139.8% | 43.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
120.2%
EPS terminal req.
$1.55
Spread vs growth
-104.7%
5Y implied EPS CAGR
66.8%
EPS terminal req.
$1.87
Spread vs growth
-51.3%
10Y implied EPS CAGR
35.5%
EPS terminal req.
$3.01
Spread vs growth
-19.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.4%
Start / end P/E
105.9x → 120.4x
EPS bridge
0.13 → 0.14
Residual
+2.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.